HIV-1 DNA predicts disease progression and post-treatment virological control
…, W Stöhr, N Robinson, H Brown, M Fisher, S Kinloch… - elife, 2014 - elifesciences.org
10.7554/eLife.03821.001 In HIV-1 infection, a population of latently infected cells facilitates
viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in …
viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in …
[HTML][HTML] Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
…, N Robinson, H Brown, M Fisher, S Kinloch… - Nature …, 2015 - nature.com
Abstract Treatment of HIV-1 infection with antiretroviral therapy (ART) in the weeks following
transmission may induce a state of ‘post-treatment control’ (PTC) in some patients, in whom …
transmission may induce a state of ‘post-treatment control’ (PTC) in some patients, in whom …
[HTML][HTML] Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection
…, N Robinson, H Brown, M Fisher, S Kinloch… - PLoS …, 2016 - journals.plos.org
The rate at which HIV-1 infected individuals progress to AIDS is highly variable and impacted
by T cell immunity. CD8 T cell inhibitory molecules are up-regulated in HIV-1 infection and …
by T cell immunity. CD8 T cell inhibitory molecules are up-regulated in HIV-1 infection and …
[HTML][HTML] Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
…, P Pellegrino, L Waters, F Burns, S Kinloch… - Nature …, 2021 - nature.com
There is an urgent need to understand the nature of immune responses against SARS-CoV-2,
to inform risk-mitigation strategies for people living with HIV (PLWH). Here we show that …
to inform risk-mitigation strategies for people living with HIV (PLWH). Here we show that …
[HTML][HTML] Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV
…, L Muir, P Pellegrino, L Waters, F Burns, S Kinloch… - The lancet HIV, 2021 - thelancet.com
SARS-CoV-2 infection elicits similar antibody responses in HIV-negative individuals and
people living with HIV that is well controlled by antiretroviral therapy (ART). 1 SARS-CoV-2 …
people living with HIV that is well controlled by antiretroviral therapy (ART). 1 SARS-CoV-2 …
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection
R Tilling, S Kinloch, LE Goh, D Cooper, L Perrin… - Aids, 2002 - journals.lww.com
Objectives To monitor changes in the numbers of CD8 lymphocytes expressing the activated
CD38++ phenotype in peripheral blood samples from patients with primary HIV infection (…
CD38++ phenotype in peripheral blood samples from patients with primary HIV infection (…
[PDF][PDF] Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles
We assessed a cohort of people living with human immunodeficiency virus (PLWH) (n = 110)
and HIV negative controls (n = 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all …
and HIV negative controls (n = 64) after 1, 2 or 3 SARS-CoV-2 vaccine doses. At all …
Depression, lifestyle factors and cognitive function in people living with HIV and comparable HIV‐negative controls
…, N Hemat, M Jones, A Carroll, S Kinloch… - HIV …, 2019 - Wiley Online Library
Objectives We investigated whether differences in cognitive performance between people
living with HIV ( PLWH ) and comparable HIV ‐negative people were mediated or moderated …
living with HIV ( PLWH ) and comparable HIV ‐negative people were mediated or moderated …
Low Levels of Perforin Expression in CD8+ T Lymphocyte Granules in Lymphoid Tissue during Acute Human Immunodeficiency Virus Type 1 Infection
J Andersson, S Kinloch, A Sönnerborg… - The Journal of …, 2002 - academic.oup.com
Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte (CTL) responses are
detectable shortly after the acute phase of HIV infection, but they cannot control viral …
detectable shortly after the acute phase of HIV infection, but they cannot control viral …
Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial
…, E Lathouwers, GM Foster, R Yakoob, S Kinloch… - HIV Clinical …, 2013 - Taylor & Francis
Background: In patients receiving combination antiretroviral therapy (ART), switching to
monotherapy with ritonavir-boosted darunavir (DRV/r) can maintain plasma HIV-1 RNA …
monotherapy with ritonavir-boosted darunavir (DRV/r) can maintain plasma HIV-1 RNA …